Antiparkinsonian Activity Of Vitamin D3 And Pregabalin Against Rotenone Induced Parkinsonism In Rat Model
Main Article Content
Abstract
Rotenone is a potent specific inhibitor of mitochondrial complex-1 that appears to reproduce the behavioural features of Parkinson's disease in rats. It selectively destroys dopaminergic neurons, causing a deficiency of dopamine in the striatum which leads to impaired motor functions include tremor and muscle rigidity. The purpose of this study was to assess if pregabalin affects Parkinson's disease. Long-term use of neuroleptics in psychotic disorders such as schizophrenia results in extrapyramidal symptoms such as Parkinson's disease and neuropathic pain. The present study deals with the antiparkinson effect of Vitamin D3, Pregabalin on rotenone induced Parkinson disease in wister rats. Neural degeneration was induced in a group (II, III, IV) by Rotenone (2.5mg/kg daily i.p.) for 28 days. Group II: Vitamin D3 (30mg/kg); Group III Pregabalin (30mg/kg); Vitamin D3 (30 mg/kg p.o.) and pregabalin (30 mg/kg p.o.) drug treatment significantly improved these behavioural and biochemical alterations restored mitochondrial enzyme complex activities and attenuated neuroinflammatory markers in rotenone (2.5mg/kg) treated animals as compared to control group. It can be concluded that the Vitamin D3 (30mg/kg) showed highly significant decrease oxidative stress (MDA level)) and significantly increase dopamine level of post-treatment. The pregabalin (30mg/kg) showed significant increase locomotor activity and Rota rod test.
Article Details
References
Malaiwong, N., Chalorak, P., Jattujan, P., Manohong, P., Niamnont, N., Suphamungmee, W., Sobhon, P., & Meemon, K. (2019). AntiParkinson activity of bioactive substances extracted from Holothuria leucospilota. Biomedicine &
Pharmacotherapy, 109, 1967–1977. https:// doi.org/10.1016/j.biopha.2018.11.063.
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.- E., & Lang, A. E. (2017). Parkinson disease. Nature Reviews Disease Primers, 3(1), 1–21. https://doi.org/10.1038/ nrdp.2017.13.
Vegeto E, Benedusi V, Maggi A. Estrogen anti-inflammatory activity in brain: A therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol 2008;29(4):507-19
Shibeshi W, Makonnen E, Zerihun L, Debella A. Effect of Achyranthes aspera L. on fetal abortion, uterine and pituitary weights, serum lipids and hormones. Afr Health Sci 2006;6(2):108-12.
Akhtar MS, Iqbal J. Evaluation of the hypoglycaemic effect of Achyranthes aspera in normal and alloxan-diabetic rabbits. J Ethnopharmacol 1991;31(1):49-57
Chitra et al EFFECT OF HYDROALCOHOLIC EXTRACT OF ACHYRANTHES ASPERA ON HALOPERIDOLINDUCED PARKINSON’S DISEASE IN WISTAR RATS Asian Pharm Clin Res, Vol 10, Issue 9, 2017, 318-321 https://www.researchgate.net/publication/319432776
Olanow CW, Schapira A, Agid Y. Causes of cell death and prospects for neuroprotection in Parkinson’s disease. Ann Neurol. 2003;53 (suppl 3):1–170.
Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology. 1996;47(6 suppl 3):S161–S170.
Schapira AH, Olanow CW, Greenamyre JT, Bezard E. Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: future therapeutic perspectives. Lancet. 2014;384(9942):545–555.
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306.
Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52:381–389
Hensley K, Pye QN, Maidt ML, Stewart CA, Robinson KA, Jaffrey F, Floyd RA (1998) Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J Neurochem 71:2549–2557
Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, Parks JP, Parker Jr WD, Bennett Jr JP (1997) Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson’s disease. Biochim Biophys Acta 1362:77–86.
Pregabalin drug profile:- https://go.drugbank.com/drugs/DB00126
Bayo-Olugbami, A., Nafiu, A., B, Amin, A. et al. (2022). Vitamin D attenuated 6-OHDA-induced behavioural deficits, dopamine dysmetabolism, oxidative stress, and neuro-inflammation in mice. Nutr Neurosci 25(4): 823-834.
Golan, D., Staun-Ram, E., Glass-Marmor, L. et al. (2013). The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav Immun 32:180-5.
Owoyele B.V Cholecalciferol (VD3) Attenuates L-DOPA-Induced Dyskinesia in Parkinsonian Mice Via Modulation of Microglia and OxidoInflammatory Mechanisms Niger. J. Physiol. Sci. 37 https://doi.org/10.54548/njps.v37i2.3.
Shreesh Ojha ,Hayate Javed, Neuroprotective potential of ferulic acid in the rotenone model of Parkinson’s disease Drug Design, Development and Therapy http://dx.doi.org/10.2147/DDDT.S90616
Manar A Nader Sitagliptin enhances the neuroprotective effect of Pregabalin against pentylenetetrazole-induced acute epileptogenesis in mice: implication of oxidative, inflammatory, apoptotic and autophagy pathways Neurochemistry
International S0197-0186(17)30370-4 DOI: 10.1016/j.neuint.2017.10.006
Fujikawa T, Kanada N, Shimada A, et al. Effect of sesamin in Acanthopanax senticosus HARMS on behavioral dysfunction in rotenoneinduced parkinsonian rats. Biol Pharm Bull. 2005;28(1):169–172.
Tsuneyasu Kobayashi EFFECTS OF L-DOPA AND BROMOCRIPTINE ON HALOPERIDOL-INDUCED MOTOR DEFICITS IN MICE Motor Detieits and Anti-parkinsonianDrugs Vol. 61,No. 26, 1997.
H.A. Adedeji et al. Novel action of metformin in the prevention of haloperidolinduced catalepsy in mice: Potential in the treatment of Parkinson's disease? Progress in NeuroPsychopharmacology & Biological Psychiatry
http://dx.doi.org/10.1016/j.pnpbp.2013.10.014.
Costall, B., Naylor, R.J., 1974. On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacologia 34, 233–241.
Manoj kumar Mishra et al Effect of nulumbo nucifera rhizome extract in haloperidol induced Parkinson rat model Journal of pharmaceutical 2022 DOI:10..47750/pnr.2022.13.S02.01
Kulkarni, S.K., 1999. Handbook of Experimental Pharmacology, 3rd edn. Vallabh Prakashan, Delhi.
Sinha AK. Colorimetric assay of catalase. Anal Biochem 1972;47(2):389-94. 23.
H.A. Adedeji et al novel action of metformin in the prevention of haloperidolinduced catalepsy in mice: potential in the treatment of parkinson’s disease?
Yong, R., Liu, Ren Wenhua, Jiang, Houbo, Jiang, Qian, Feng, Jian, 2005. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 280 (40), 34105–34112
Sherer, T.B., Betarberbet, R., Tasta, C.M., Seo, B.B., Richardson, J.R., Kim, J.H., Miller, G.W., Yagi, T., Yagi, A.M., Greenamyre, J.T., 2003. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (340), 0756– 10764.
Ludolph, A.C, He, F., Spencer, P.S, Hammerstad, J., Sabri, M, 1991. 3nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18 (4), 492–498.
Sarkozi et al Green tea and vitamin c ameliorate some neuro -functional and biochemical signs of arsenic toxicity in rats
Vivek Verma, Nirmal Singh, and Amteshwar Singh Jaggi*Pregabalin in NeuropathicPain: Evidences and Possible Mechanisms